Recent Advance of the Hepatitis B Virus Inhibitors: A Medicinal Chemistry Overview
Future Medicinal Chemistry2015Vol. 7(5), pp. 587–607
Citations Over TimeTop 15% of 2015 papers
Abstract
Hepatitis B Virus (HBV) is one of the most prevalent viral infections of human worldwide. The therapies are limited in the clinical context because of negative side effects of interferons and the development of viral resistance to the nucleoside/nucleotide inhibitors. In this review, we summarize the recent advances in design and development of potent anti-HBV inhibitors from natural sources and synthetic compounds, targeting different steps in the life cycle of HBV. We attempt to emphasize the major structural modifications, mechanisms of action and computer-aided docking analysis of novel potent inhibitors that need to be addressed in the future to design potent anti-HBV molecules.
Related Papers
- → Docking of Macrocycles: Comparing Rigid and Flexible Docking in Glide(2017)82 cited
- → Protein docking prediction using predicted protein-protein interface(2012)77 cited
- → GAsDock: a new approach for rapid flexible docking based on an improved multi-population genetic algorithm(2004)57 cited
- → Integrated Control and Docking Mechanism for Docking-Undocking Drones in the Air(2022)2 cited
- → Prediction of Protein-compound Complex Structures by Docking Simulation(2011)